JERUSALEM--(BUSINESS WIRE)--Jan. 5, 2016--
Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) announced the launch of
a generic equivalent of Ortho Tri-Cyclen® Lo
(norgestimate/ethinyl estradiol) tablets in the United States. Teva’s
Tri-Lo-Sprintec® (norgestimate and ethinyl estradiol tablets,
USP) is an oral contraceptive, available in a 28-day blister pack
dispenser, used by women to prevent pregnancy.
As a leading global pharmaceutical company, Teva is committed to care in
women’s health with a portfolio including contraceptive products and
other therapies.
Ortho Tri-Cyclen® Lo (norgestimate/ethinyl estradiol)
tablets, marketed by Janssen Pharmaceuticals, Inc., had annual sales of
approximately $488 million in the United States, according to IMS data
as of October 2015.
About Tri-Lo-Sprintec®
Tri-Lo-Sprintec is indicated for use by females of reproductive
potential to prevent pregnancy. Tri-Lo-Sprintec does not protect against
HIV infection (AIDS) and other sexually transmitted diseases.
Important Safety Information
Cigarette smoking increases the risk of serious cardiovascular side
effects from combination oral contraceptive (COC) use. This risk
increases with age, particularly in women over 35 years of age and with
the number of cigarettes smoked. For this reason, COCs are
contraindicated in women who are over 35 years of age and smoke.
Tri-Lo-Sprintec is contraindicated in women who are known to have the
following conditions: a high risk of arterial or venous thrombotic
diseases; liver tumors, benign or malignant, or liver disease;
undiagnosed abnormal uterine bleeding; pregnancy; or breast cancer or
other estrogen- or progestin-sensitive cancer, now or in the past.
Serious adverse reactions associated with the use of COCs include:
thromboembolic disorders and other vascular problems; impaired liver
function or liver tumors; hypertension, gallbladder disease;
carbohydrate and lipid metabolic effects; new or worsening of headaches,
including migraines; bleeding irregularities and amenorrhea, depression;
carcinoma of breast and cervix; elevations of binding globulins,
angioedema, and chloasma.
The most common adverse events reported during clinical trials (≥2%)
were: headache/migraine, nausea/vomiting, breast issues, abdominal pain,
menstrual disorders, mood disorders, acne, vulvovaginal infection,
abdominal distension, weight increased, and fatigue.
For more information, please see accompanying full Prescribing
Information, including Boxed Warning.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading
global pharmaceutical company that delivers high-quality,
patient-centric healthcare solutions to millions of patients every day.
Headquartered in Israel, Teva is the world’s largest generic medicines
producer, leveraging its portfolio of more than 1,000 molecules to
produce a wide range of generic products in nearly every therapeutic
area. In specialty medicines, Teva has a world-leading position in
innovative treatments for disorders of the central nervous system,
including pain, as well as a strong portfolio of respiratory products.
Teva integrates its generics and specialty capabilities in its global
research and development division to create new ways of addressing unmet
patient needs by combining drug development capabilities with devices,
services and technologies. Teva's net revenues in 2014 amounted to $20.3
billion. For more information, visit www.tevapharm.com.
Teva's Safe Harbor Statement under the U. S. Private Securities
Litigation Reform Act of 1995:
This release contains forward-looking statements, which are based on
management’s current beliefs and expectations and involve a number of
known and unknown risks and uncertainties that could cause our future
results, performance or achievements to differ significantly from the
results, performance or achievements expressed or implied by such
forward-looking statements. Important factors that could cause or
contribute to such differences include risks relating to: our ability to
develop and commercialize additional pharmaceutical products;
competition for our innovative products, especially Copaxone®
(including competition from orally-administered alternatives, as well as
from potential purported generic equivalents) and our ability to
migrate users to our 40 mg/mL version; the possibility of material
fines, penalties and other sanctions and other adverse consequences
arising out of our ongoing FCPA investigations and related matters; our
ability to achieve expected results from the research and development
efforts invested in our pipeline of specialty and other products; our
ability to reduce operating expenses to the extent and during the
timeframe intended by our cost reduction program; our ability to
identify and successfully bid for suitable acquisition targets or
licensing opportunities, or to consummate and integrate acquisitions;
the extent to which any manufacturing or quality control problems damage
our reputation for quality production and require costly remediation;
increased government scrutiny in both the U.S. and Europe of our patent
settlement agreements; our exposure to currency fluctuations and
restrictions as well as credit risks; the effectiveness of our patents,
confidentiality agreements and other measures to protect the
intellectual property rights of our specialty medicines; the effects of
reforms in healthcare regulation and pharmaceutical pricing,
reimbursement and coverage; governmental investigations into sales and
marketing practices, particularly for our specialty pharmaceutical
products; adverse effects of political or economic instability, major
hostilities or acts of terrorism on our significant worldwide
operations; interruptions in our supply chain or problems with internal
or third-party information technology systems that adversely affect our
complex manufacturing processes; significant disruptions of our
information technology systems or breaches of our data security;
competition for our generic products, both from other pharmaceutical
companies and as a result of increased governmental pricing pressures;
competition for our specialty pharmaceutical businesses from companies
with greater resources and capabilities; the impact of continuing
consolidation of our distributors and customers; decreased opportunities
to obtain U.S. market exclusivity for significant new generic products;
potential liability in the U.S., Europe and other markets for sales of
generic products prior to a final resolution of outstanding patent
litigation; our potential exposure to product liability claims that are
not covered by insurance; any failure to recruit or retain key
personnel, or to attract additional executive and managerial talent; any
failures to comply with complex Medicare and Medicaid reporting and
payment obligations; significant impairment charges relating to
intangible assets, goodwill and property, plant and equipment; the
effects of increased leverage and our resulting reliance on access to
the capital markets; potentially significant increases in tax
liabilities; the effect on our overall effective tax rate of the
termination or expiration of governmental programs or tax benefits, or
of a change in our business; variations in patent laws that may
adversely affect our ability to manufacture our products in the most
efficient manner; environmental risks; and other factors that are
discussed in our Annual Report on Form 20-F for the year ended December
31, 2014 and in our other filings with the U.S. Securities and Exchange
Commission. Forward-looking statements speak only as of the date on
which they are made and we assume no obligation to update or revise any
forward-looking statement, whether as a result of new information,
future events or otherwise.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160105005786/en/
Source: Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
IR:
United States
Kevin
C. Mannix, 215-591-8912
Ran Meir, 215-591-3033
or
Israel
Tomer
Amitai, 972 (3) 926-7656
or
PR:
Israel
Iris
Beck Codner, 972 (3) 926-7687
or
United States
Denise
Bradley, 215-591-8974
Nancy Leone, 215-284-0213